Blog
RSS FeedPosted by Michael Wonder on 27 Jan 2021
E.U. and U.K. fighting over scarce vaccines
27 January 2021 - As vaccine production falls behind schedule, and the European Union lags in inoculating people, Brussels and London ...
Posted by Michael Wonder on 28 Jan 2021
Alberta announces funding for pricey gene therapy drug Zolgensma
Alberta Health Minister Tyler Shandro announced funding Wednesday for the gene therapy Zolgensma, which is used to treat toddlers with ...
Posted by Michael Wonder on 27 Jan 2021
On the role of cost effectiveness thresholds in health care priority setting
25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...
Posted by Michael Wonder on 27 Jan 2021
NICE publishes final guidance on new use for Lonsurf
27 January 2021 - NICE has completed its review of trifluridine with tipiracil hydrochloride for the treatment of patients with ...
Posted by Michael Wonder on 27 Jan 2021
EU demands UK made AstraZeneca vaccine doses
27 January 2021 - The EU has urged pharmaceutical firm AstraZeneca to supply it with more doses of its COVID-19 ...
Posted by Michael Wonder on 27 Jan 2021
European Medicines Agency accepts GBT’s marketing authorisation application for Oxbryta (voxelotor) for the treatment of haemolytic anemia in sickle cell disease
27 January 2021 - Global Blood Therapeutics today announced that the EMA has completed the validation of GBT’s marketing authorisation application ...
Posted by Michael Wonder on 27 Jan 2021
Coronavirus: EU threat to Australia’s vaccine program
27 January 2021 - A European move to shore up supplies of both the Pfizer/BioNTech and Oxford/AstraZeneca vaccines looks to ...
Posted by Michael Wonder on 27 Jan 2021
Australia’s COVID-19 vaccine information campaign begins
27 January 2021 - The Australian Government’s $23.9 million public information campaign to encourage Australians to get a COVID-19 vaccine begins ...
Posted by Michael Wonder on 27 Jan 2021
Government rejects claim overseas production issues threaten access to vaccines
27 January 2021 - The entire population could be vaccinated against COVID-19 in as little as 6½ months, meaning it's ...
Posted by Michael Wonder on 27 Jan 2021
European Commission approves Keytruda (pembrolizumab) as first-line treatment in adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
26 January 2021 - Keytruda is first checkpoint inhibitor approved in Europe to treat MSI-H or dMMR colorectal cancer. ...
Posted by Michael Wonder on 27 Jan 2021
NICE recommends Revlimid for newly diagnosed multiple myeloma patients
27 January 2021 - Bristol Myers Squibb’s Revlimid (lenalidomide) has received a recommendation from the UK’s NICE for newly diagnosed ...
Posted by Michael Wonder on 27 Jan 2021
Will Canadians get to choose which COVID-19 vaccine they get?
26 January 2021 - Two vaccines are already approved, two are under review, and two more are in the pipeline, ...
Posted by Michael Wonder on 27 Jan 2021
Alleviant Medical receives breakthrough device designation from FDA for transcatheter technology
25 January 2021 - Alleviant Medical today announced that the US FDA has granted the company a breakthrough device designation ...
Posted by Michael Wonder on 27 Jan 2021
PEDRA Technology receives FDA breakthrough device designation for its PEDRA Xauron real-time tissue perfusion system
25 January 2021 - Novel perfusion monitor achieves FDA breakthrough device Designation for real-time, peri-procedural monitoring of tissue perfusion in patients ...
Posted by Michael Wonder on 26 Jan 2021
Scott Morrison says Australia will not be a hostage to global vaccine shortages
26 January 2021 - Scott Morrison has revealed why Australia won’t be “completely hostage” to overseas vaccine schedules and shortages. ...